Items Tagged ‘jakafi’

June 21st, 2016

Jakafi Superior to Standard Treatment in Polycythemia Vera

By

Treatment with Jakafi® (ruxolitinib) was superior to best available treatment among patients with inadequately controlled polycythemia vera (PV). These results were recently presented at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark. PV is a type of myeloproliferative neoplasm (MPN) in which the body produces a larger than normal amount of […]

View full entry

Tags: jakafi, mpn, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, ruxolitinib


June 7th, 2016

Jakafi Significantly Improves Long-Term Outcomes in Myelofibrosis

By

The agent Jakafi® (ruxolitinib) has demonstrated significant improvements in long-term outcomes for patients diagnosed with myelofibrosis. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Myelofibrosis (MF) is a type of blood cancer known as a myeloproliferative neoplasm that is chronic and progressive in nature. It involves the […]

View full entry

Tags: 2016, asco, blood cancer, COMFORT 1, jakafi, myelofibrosis, Myeloproliferative Neoplasms MPN, News


February 10th, 2016

Year in Review: Myeloproliferative Neoplasms

By

Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms, life-threatening complications, and are at risk of progression to acute leukemia. The development and approval of the JAK2 inhibitor Jakafi® (Ruxolitinib) has led to more effective management of these symptoms in many patients with PV, positively […]

View full entry

Tags: essential thrombocythemia, jakafi, mpn, myelofibrosis, Myeloproliferative Neoplasms MPN, News, polycythemia vera, research, review


December 29th, 2015

All Symptomatic Polycythemia Vera Patients May Benefit From Treatment with a JAK2 Inhibitor

By

Patients with polycythemia vera (PV) experience significant symptoms characterized by fatigue, itching, night sweats, bone pain, fever, and undesired weight loss that contribute to a poor quality of life which is often under appreciated by family and providers. Until recently, PV patients’ only treatment options were phlebotomy and hydroxyurea (HU). However, the development and approval […]

View full entry

Tags: jakafi, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, ruxolitinib, treatment


July 7th, 2015

Jakafi® Appears Safe and Effective in Long-Term Disease Control in Polycythemia Vera

By

In patients with polycythemia vera (PV), the drug Jakafi® (ruxolitinib) can help control disease at least one year. These findings were presented at the 20th Congress of the European Hematology Association in Vienna, Austria, June 11–14, 2015.[1] Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called […]

View full entry

Tags: blood cancer, clinical trials, hydrea, jakafi, MPNs, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, ruxolitinib


April 21st, 2015

What you Need to Know about Itching and Myeloproliferative Neoplasms

By

What you Need to Know about Itching and Myeloproliferative Neoplasms If you have been diagnosed with myelofibrosis or polycythemia vera, you may have experienced itching as a side effect. Itching occurs as a result of the activity of cytokines (small proteins involved in cell signaling) associated with myeloproliferative neoplasms (MPNs) and because a certain type […]

View full entry

Tags: itching, jakafi, mpn, myelofibrosis, Myeloproliferative Neoplasms MPN, News, polycythemia vera, ruxolutinib


April 14th, 2015

Jakafi® Provides Important Symptom Relief in Patients with Polycythemia Vera

By

A Phase III trial finds that Jakafi® (ruxolitinib) more effectively controls symptoms than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England Journal of Medicine. Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called myeloproliferative neoplasms (MPN). In these […]

View full entry

Tags: blood cancer, hydrea, hydroxyurea, improvement, jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, ruxolitinib


February 17th, 2015

Phase III Trial Finds Jakafi Superior to Standard Therapy for Polycythemia Vera

By

A Phase III trial finds that Jakafi® (ruxolitinib) is more effective than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England Journal of Medicine. Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called myeloproliferative neoplasms (MPN). In these disorders, […]

View full entry

Tags: hydrea, hydroxyurea, jak1, JAK2, jakafi, mpn, Myeloproliferative Neoplasms MPN, myeloproliferative neoplastms, News, polycythemia vera, PV, PV treatment


January 22nd, 2015

Myeloproliferative Neoplasms: Making Progress in Polycythemia Vera and Myelofibrosis

By

Myeloproliferative neoplasms (MPN) are a related group of blood cancers. In these disorders, the bone marrow cells that produce blood cells develop and function abnormally. The three main types of MPN are polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). In addition to developing on its own, myelofibrosis may also develop as a […]

View full entry

Tags: jakafi, mpn, myelofibrosis, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV


December 16th, 2014

Jakafi® Helps Maintain Blood Cells Levels in Polycythemia Vera

By

CancerConnect News: A new drug called Jakafi® (ruxolitinib) appears to help patients with polycythemia vera (PV) maintain hematocrit control more effectively than best available therapy. These findings were presented at the 56th American Hematology Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California.[1] Polycythemia vera is a slow-growing type of blood cancer […]

View full entry

Tags: jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, ruxolitinib


December 15th, 2014

Switching from Best Available Therapy to Jakafi® Improves Outcomes in Polycythemia Vera

By

Patients with polycythemia vera (PV) who begin treatment with best available therapy and then switch to treatment with Jakafi® (ruxolitinib) experience improved outcomes. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California. Polycythemia vera is a slow-growing type of blood cancer that belongs […]

View full entry

Tags: jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV


December 11th, 2014

Jakafi® Appears Effective in the Treatment of Essential Thrombocythemia

By

By interfering with protein signaling linked to blood cell production, Jakafi® (ruxolitinib) may be effective in the treatment of essential thrombocythemia (ET) in patients who progress on or can’t tolerate Hydrea® (hydroxyurea). These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California. Essential thrombocythemia […]

View full entry

Tags: jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, ruxolitinib


December 5th, 2014

Jakafi: First Drug Approved for Treatment of Polycythemia Vera

By

The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition. Polycythemia vera occurs when too many red blood cells are made in the bone marrow. Patients […]

View full entry

Tags: jakafi, mpn, Myeloproliferative Neoplasms MPN, News, PV


August 6th, 2014

FDA Accepts Supplemental New Drug Application for Jakafi and Priority Review Granted for the Treatment of Polycythemia Vera

By

The  U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for Jakafi® (ruxolitinib) as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. PV is a myeloproliferative neoplasm (MPN) characterized by an overproduction of normal red […]

View full entry

Tags: Info Type, jakafi, mpn, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, ruxolitinib


July 30th, 2014

Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Information

By

Jakafi is a prescription medicine approved by the U.S. Food and Drug Administration to treat people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF.  It was announced today that the U.S. Food & Drug Administration (FDA) has approved supplemental labeling for Jakafi® to include new overall survival […]

View full entry

Tags: jakafi, mpn, Myeloproliferative Neoplasms MPN, News